Stomach cancer drug combo shows promise in new trial
NCT ID NCT04882241
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the drug pembrolizumab to standard chemotherapy helps Chinese adults with stomach or gastroesophageal junction cancer. Participants received the drug combination or a placebo before and after surgery. The goal was to see if the combination improves outcomes like preventing cancer from returning.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Afflilated Hospital of Bengbu Medical College-Surgical Oncology (Site 0638)
Bengbu, Anhui, 233004, China
-
Beijing Cancer Hospital ( Site 0221)
Beijing, Beijing Municipality, 100142, China
-
Beijing Friendship Hospital ( Site 0637)
Beijing, Beijing Municipality, 100050, China
-
Fourth Hospital of Hebei Medical University ( Site 0633)
Shijiazhuang, Hebei, 050035, China
-
Fujian Medical University Union Hospital-1 Bingfanglou-Gastric Surgery Department (Site 0632)
Fuzhou Fujian, Fujian, 350001, China
-
Fujian Provincial Cancer Hospital ( Site 0230)
Fuzhou, Fujian, 350014, China
-
Henan Cancer Hospital (Site 0227)
Zhengzhou, Henan, 450008, China
-
Renji Hospital Shanghai Jiao Tong University School of Medicine ( Site 0642)
Shanghai, Shanghai Municipality, 200127, China
-
Shandong Provincial Hospital-Gastrointestinal Surgery ( Site 0640)
Jinan, Shandong, 250001, China
-
Sichuan Cancer hospital
Chengdu, Sichuan, 610041, China
-
Sir Run Run Shaw Hospital ( Site 0233)
Hangzhou, Zhejiang, 430030, China
-
Tangdu Hospital of Fourth Military Medical University of Chinese People's Liberation Army ( Site 0647)
Xi'an, Shaanxi, 710038, China
-
The Affiliated Hospital of Qingdao University ( Site 0636)
Qingdao, Shandong, 266003, China
-
The Affiliated Hospital of Xuzhou Medical College-Oncology ( Site 0645)
Xuzhou, Jiangsu, 221006, China
-
The First Affiliated Hospital of Guangzhou Medical University ( Site 0224)
Guangzhou, Guangdong, 510120, China
-
The First Affiliated Hospital of Wenzhou Medical University (Site 0652)
Wenzhou, Zhejiang, 32500, China
-
The First Affiliated Hospital, Sun Yat-sen University (Site 0635)
Guangzhou, Guangdong, 510080, China
-
The First Hospital of Jilin University-Gastrointestinal Surgery ( Site 0234)
Changchun, Jilin, 130021, China
-
Zhejiang Cancer Hospital ( Site 0231)
Hangzhou, Zhejiang, 310022, China
-
Zhejiang Provincial People's Hospital-Oncology (Site 0656)
Hangzhou, Zhejiang, 310014, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can surgery for stomach or esophageal cancer cloud the mind?